S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
CNSX:QCC

Quadron Cannatech Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.27
MA: $0.27
$0.27
52-Week Range N/A
VolumeN/A
Average Volume32,330 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Quadron Cannatech (CNSX:QCC) Vs. VMD, TMD, HTL, PTQ, PHM, and HSM

Should you be buying QCC stock or one of its competitors? Companies in the industry of "medical devices" are considered alternatives and competitors to Quadron Cannatech, including Viemed Healthcare (VMD), Titan Medical Inc. (TMD.TO) (TMD), Hamilton Thorne (HTL), Protech Home Medical (PTQ), Protech Home Medical (PHM), and Helius Medical Technologies (HSM).

Viemed Healthcare (TSE:VMD) and Quadron Cannatech (CNSX:QCC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Viemed Healthcare and Quadron Cannatech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed HealthcareC$121.56 million3.97$28.56 millionC$0.7216.90
Quadron CannatechN/AN/AN/AN/AN/A

Viemed Healthcare has higher revenue and earnings than Quadron Cannatech.

Profitability

This table compares Viemed Healthcare and Quadron Cannatech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viemed HealthcareN/AN/AN/A
Quadron CannatechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Viemed Healthcare and Quadron Cannatech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viemed Healthcare01002.00
Quadron Cannatech0000N/A

Summary

Viemed Healthcare beats Quadron Cannatech on 1 of the 1 factors compared between the two stocks.

Titan Medical Inc. (TMD.TO) (TSE:TMD) and Quadron Cannatech (CNSX:QCC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Titan Medical Inc. (TMD.TO) and Quadron Cannatech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Titan Medical Inc. (TMD.TO)C$20 million14.73$-39,538,525.00C($0.36)-7.45
Quadron CannatechN/AN/AN/AN/AN/A

Quadron Cannatech has lower revenue, but higher earnings than Titan Medical Inc. (TMD.TO).

Profitability

This table compares Titan Medical Inc. (TMD.TO) and Quadron Cannatech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Titan Medical Inc. (TMD.TO)N/AN/AN/A
Quadron CannatechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Titan Medical Inc. (TMD.TO) and Quadron Cannatech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Titan Medical Inc. (TMD.TO)0000N/A
Quadron Cannatech0000N/A

Summary

Titan Medical Inc. (TMD.TO) beats Quadron Cannatech on 1 of the 1 factors compared between the two stocks.

Hamilton Thorne (CVE:HTL) and Quadron Cannatech (CNSX:QCC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Hamilton Thorne and Quadron Cannatech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hamilton ThorneC$38.36 million6.28$968,653.00C$0.01248.57
Quadron CannatechN/AN/AN/AN/AN/A

Hamilton Thorne has higher revenue and earnings than Quadron Cannatech.

Profitability

This table compares Hamilton Thorne and Quadron Cannatech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hamilton ThorneN/AN/AN/A
Quadron CannatechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Hamilton Thorne and Quadron Cannatech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hamilton Thorne00403.00
Quadron Cannatech0000N/A

Hamilton Thorne currently has a consensus target price of C$1.82, suggesting a potential upside of 4.37%.

Summary

Hamilton Thorne beats Quadron Cannatech on 2 of the 2 factors compared between the two stocks.

Quadron Cannatech (CNSX:QCC) and Protech Home Medical (CVE:PTQ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Quadron Cannatech and Protech Home Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quadron CannatechN/AN/AN/AN/AN/A
Protech Home MedicalC$97.76 million2.42C$-8,245,376.00C($0.07)-28.65

Quadron Cannatech has higher earnings, but lower revenue than Protech Home Medical.

Profitability

This table compares Quadron Cannatech and Protech Home Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quadron CannatechN/AN/AN/A
Protech Home MedicalN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Quadron Cannatech and Protech Home Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quadron Cannatech0000N/A
Protech Home Medical00503.00

Protech Home Medical has a consensus price target of C$2.58, suggesting a potential upside of 21.86%.

Summary

Protech Home Medical beats Quadron Cannatech on 2 of the 2 factors compared between the two stocks.

Quadron Cannatech (CNSX:QCC) and Protech Home Medical (CVE:PHM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Quadron Cannatech and Protech Home Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quadron CannatechN/AN/AN/AN/AN/A
Protech Home MedicalC$77.14 million0.62C$833,022.00C$0.0057.50

Protech Home Medical has higher revenue and earnings than Quadron Cannatech.

Profitability

This table compares Quadron Cannatech and Protech Home Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quadron CannatechN/AN/AN/A
Protech Home MedicalN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Quadron Cannatech and Protech Home Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quadron Cannatech0000N/A
Protech Home Medical0000N/A

Summary

Protech Home Medical beats Quadron Cannatech on 1 of the 1 factors compared between the two stocks.

Quadron Cannatech (CNSX:QCC) and Helius Medical Technologies (TSE:HSM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Quadron Cannatech and Helius Medical Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quadron CannatechN/AN/AN/AN/AN/A
Helius Medical TechnologiesC$622,000.0065.17C$-38,078,347.00C($16.48)-1.06

Quadron Cannatech has higher earnings, but lower revenue than Helius Medical Technologies.

Profitability

This table compares Quadron Cannatech and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quadron CannatechN/AN/AN/A
Helius Medical TechnologiesN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Quadron Cannatech and Helius Medical Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quadron Cannatech0000N/A
Helius Medical Technologies0000N/A

Summary

Helius Medical Technologies beats Quadron Cannatech on 1 of the 1 factors compared between the two stocks.


Quadron Cannatech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
VMD
Viemed Healthcare
0.3$12.20flatC$489.78 millionC$121.56 million16.90Gap Down
TMD
Titan Medical Inc. (TMD.TO)
0.8$2.69flatC$293.53 millionC$20 million-7.45Gap Down
HTL
Hamilton Thorne
1.2$1.74flatC$165.83 millionC$38.36 million248.57
PTQ
Protech Home Medical
1.2$2.12flatC$94.56 millionC$97.76 million-28.65Upcoming Earnings
Gap Down
PHM
Protech Home Medical
0.5$0.12flatC$50.12 millionC$77.14 million57.50News Coverage
Gap Up
HSM
Helius Medical Technologies
0.5$17.54flatC$40.65 millionC$622,000.00-1.06
ASG
Aurora Spine
0.6$0.91flatC$8.31 millionC$8.84 million-60.67News Coverage
BLO
Cannabix Technologies
0.5N/AN/AC$0.00N/A0.00Gap Up
ORTH
Ortho Regenerative Technologies
0.5N/AN/A$0.00N/A0.00High Trading Volume
Smith & Nephew logo
SNN
Smith & Nephew
0.6N/AN/A$0.00N/A0.00
VMD
Viemed Healthcare
0.5$4.95flatC$0.00N/A0.00Gap Up
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.